Kenneth Custer
Kenneth Custer is the president of Eli Lilly, a leading American pharmaceutical company known for its innovative treatments. Under his leadership, the company is advancing its research and development initiatives, including a new oral weight-loss medication called orforglipron, which has shown promising results in a recent clinical trial for obesity management. Custer emphasizes the potential of this daily pill to transform obesity care by offering a convenient alternative to existing injectable treatments.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Estonia | 1 | 8.00 | 0.09% | +0% | 1,326,539 | 1,204 | $31,000 | 28$ |
| United States | 1 | 7.00 | 0.05% | +0% | 331,002,651 | 153,313 | $21,000,000 | 9,727$ |
| Totals | 2 | 332,329,190 | 154,517 | $21,031,000 | 9,755$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Kenneth Custer, president of Lilly Cardiometabolic Health, said the company is encouraged by the results of the trial as it highlights 'the powerful effect of retatrutide' on body weight, pain and physical function.
7
Estonia:
Eli Lilly vice president Kenneth Custer stated that they are quickly moving forward with market approvals based on positive data.
8
Romania:
Dr. Kenneth Custer, representative of Eli Lilly, stated that the company intends to submit the licensing application before the end of the year.
7
Romania:
Kenneth Custer from Eli Lilly stated that they are working to transform obesity care with a potential oral therapy.
8
United Kingdom:
Dr Kenneth Custer of Eli Lilly said the company was planning to submit the drug for licensing before the end of the year.
7
United Kingdom:
Kenneth Custer, the president of Eli Lilly, discussed the potential of orforglipron in transforming obesity care.
8